{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:16:14Z","timestamp":1792001774426,"version":"4.4.0"},"reference-count":102,"publisher":"Elsevier","isbn-type":[{"value":"9780443430114","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.pbr.2025.08.011","type":"book-chapter","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:19:42Z","timestamp":1757589582000},"page":"247-276","source":"Crossref","is-referenced-by-count":2,"title":["Precision therapeutics for Alzheimer\u2019s disease"],"prefix":"10.1016","author":[{"given":"S.","family":"Priyanka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Manjari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hemalatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ambika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyza","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buse","family":"Akt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Damla","family":"Ar\u0131san","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Manojkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib1","article-title":"APOLLOE4 phase 3 study of oral ALZ-801\/valiltramiprosate in APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease: trial design and baseline characteristics","volume":"10","author":"Abushakra","year":"2024","journal-title":"Alzheimers Dement. (N. Y.)"},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/15476286.2021.2021650","article-title":"RNA-based therapeutics for neurological diseases","volume":"19","author":"Anthony","year":"2022","journal-title":"RNA Biol."},{"issue":"2","key":"10.1016\/bs.pbr.2025.08.011_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/biomedicines11020335","article-title":"The future of precision medicine in the cure of Alzheimer\u2019s disease","volume":"11","author":"Arafah","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib4","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/bs.pbr.2025.08.011_bib5","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.1002\/alz.14063","article-title":"Pathways to personalized medicine\u2014embracing heterogeneity for progress in clinical therapeutics research in Alzheimer\u2019s disease","volume":"20","author":"Arnold","year":"2024","journal-title":"Alzheimer\u2019s & Dement"},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/JBB\/2006\/74539","article-title":"Tau phosphorylation, aggregation, and cell toxicity","volume":"2006","author":"Avila","year":"2006","journal-title":"BioMed. Res. Int."},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib7","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207958","article-title":"FDA patient-focused drug development guidances","volume":"102","author":"Berg","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/npp.2013.154","article-title":"Biomarkers in amyloid-\u03b2 immunotherapy trials in Alzheimer\u2019s disease","volume":"39","author":"Blennow","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.neumar.2025.100107","article-title":"Optimizing Alzheimer\u2019s diagnosis and precision medicine: a narrative review unlocking the potential of multiomics markers","volume":"2","author":"Braudeau","year":"2025","journal-title":"NeuroMarkers"},{"key":"10.1016\/bs.pbr.2025.08.011_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1023\/A:1011963929012","article-title":"Advances and challenges in the prevention and treatment of Alzheimer\u2019s disease","volume":"15","author":"Brinton","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/bs.pbr.2025.08.011_bib11","first-page":"20","article-title":"Impacts of FDA approval and medicare restriction on antiamyloid therapies for Alzheimer\u2019s disease: patient outcomes, healthcare costs, and drug development","author":"Brockmann","year":"2023","journal-title":"Lancet Reg. Health\u2013Am."},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41593-018-0289-8","article-title":"Tau impairs neural circuits, dominating amyloid-\u03b2 effects, in Alzheimer models in vivo","volume":"22","author":"Busche","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","article-title":"Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease","volume":"20","author":"Butterfield","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"issue":"12","key":"10.1016\/bs.pbr.2025.08.011_bib14","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1093\/hmg\/4.12.2373","article-title":"Mutations of the presenilin I gene in families with early-onset Alzheimer\u2019s disease","volume":"4","author":"Campion","year":"1995","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13287-024-03737-w","article-title":"Promoting Alzheimer\u2019s disease research and therapy with stem cell technology","volume":"15","author":"Cao","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/bs.pbr.2025.08.011_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/03946320231209839","article-title":"Novel anti-amyloid-beta (A\u03b2) monoclonal antibody lecanemab for alzheimer\u2019s disease: a systematic review","volume":"37","author":"Chowdhury","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib17","article-title":"A wearable device for assistance of Alzheimer\u2019s disease with computer aided diagnosis","volume":"10","author":"Choudhury","year":"2024","journal-title":"EAI Endorsed Trans. Pervasive Health Technol."},{"issue":"9","key":"10.1016\/bs.pbr.2025.08.011_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/bs.pbr.2025.08.011_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/bs.pbr.2025.08.011_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/bs.pbr.2025.08.011_bib21","first-page":"1","article-title":"The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease","volume":"11","author":"Cummings","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"issue":"21","key":"10.1016\/bs.pbr.2025.08.011_bib23","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2025.08.011_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/14737175.2025.2508781","article-title":"Recent therapeutic advances in the treatment and management of amyotrophic lateral sclerosis: the era of regenerative Medicine","author":"De Marchi","year":"2025","journal-title":"Expert. Rev. Neurother."},{"issue":"10-11","key":"10.1016\/bs.pbr.2025.08.011_bib25","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0531-5565(02)00141-9","article-title":"Tau aggregation in the hippocampal formation: an ageing or a pathological process?","volume":"37","author":"Delacourte","year":"2002","journal-title":"Exp. Gerontol."},{"key":"10.1016\/bs.pbr.2025.08.011_bib26","doi-asserted-by":"crossref","first-page":"1213968","DOI":"10.3389\/fnagi.2023.1213968","article-title":"A how-to guide for a precision medicine approach to the diagnosis and treatment of Alzheimer\u2019s disease","volume":"15","author":"Devi","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/bs.pbr.2025.08.011_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115283","article-title":"RNA therapies for CNS diseases","author":"Di Francesco","year":"2024","journal-title":"Adv. Drug. Delivery Rev."},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib28","article-title":"Challenges and progress in research, diagnostics, and therapeutics in Alzheimer\u2019s disease and related dementias","volume":"8","author":"Dokholyan","year":"2022","journal-title":"Alzheimer\u2019s Dementia: Transl. Res. Clin. Interventions"},{"issue":"11","key":"10.1016\/bs.pbr.2025.08.011_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70060","article-title":"The early diagnosis of Alzheimer\u2019s disease: blood-based panel biomarker discovery by proteomics and metabolomics","volume":"30","author":"Dong","year":"2024","journal-title":"CNS Neurosci. Ther"},{"issue":"8","key":"10.1016\/bs.pbr.2025.08.011_bib30","article-title":"Aducanumab as a novel treatment for Alzheimer\u2019s disease: a decade of hope, controversies, and the future","volume":"13","author":"Esang","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib31","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/su14031222","article-title":"Sustainable development goals (SDGs) as a framework for corporate social responsibility (CSR)","volume":"14","author":"Fallah Shayan","year":"2022","journal-title":"Sustainability"},{"key":"10.1016\/bs.pbr.2025.08.011_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2025.106841","article-title":"Lack of neuroprotection after systemic administration of the soluble TNF inhibitor XPro1595 in an rAAV6-\u03b1-Syn+ PFFs-induced rat model for Parkinson\u2019s disease","author":"Fredlund","year":"2025","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/bs.pbr.2025.08.011_bib33","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.14283\/jpad.2024.163","article-title":"Phase 1 studies of the Anti-Tau monoclonal antibody JNJ-63733657 in healthy participants and participants with Alzheimer\u2019s disease","volume":"11","author":"Galpern","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/bs.pbr.2025.08.011_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bionps.2023.100063","article-title":"Biomarkers of Alzheimer\u2019s disease: past, present and future clinical use","volume":"8","author":"Georgakas","year":"2023","journal-title":"Biomark. Neuropsychiatry"},{"issue":"23","key":"10.1016\/bs.pbr.2025.08.011_bib35","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","article-title":"Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease","volume":"15","author":"Gong","year":"2008","journal-title":"Curr. Medicinal Chem."},{"key":"10.1016\/bs.pbr.2025.08.011_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol. Neurodegener."},{"issue":"2","key":"10.1016\/bs.pbr.2025.08.011_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid \u03b2-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/bs.pbr.2025.08.011_bib38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"s1","key":"10.1016\/bs.pbr.2025.08.011_bib39","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.3233\/JAD-179932","article-title":"Revolution of alzheimer precision neurology. Passageway of systems biology and neurophysiology","volume":"64","author":"Hampel","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"4","key":"10.1016\/bs.pbr.2025.08.011_bib40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.pbr.2025.08.011_bib41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00702-012-0781-3","article-title":"Multidimensional plasma protein separation technique for identification of potential Alzheimer\u2019s disease plasma biomarkers: a pilot study","volume":"119","author":"Henkel","year":"2012","journal-title":"J. Neural Transm."},{"issue":"6","key":"10.1016\/bs.pbr.2025.08.011_bib42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1389450033490902","article-title":"Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer\u2019s disease","volume":"4","author":"Hoozemans","year":"2003","journal-title":"Curr. Drug. Targets"},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41541-022-00544-3","article-title":"Immunogenicity of MultiTEP platform technology-based tau vaccine in non-human primates","volume":"7","author":"Hovakimyan","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"12","key":"10.1016\/bs.pbr.2025.08.011_bib44","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1097\/JS9.0000000000002109","article-title":"Revolutionizing Medicine: recent developments and future prospects in stem-cell therapy","volume":"110","author":"Hussen","year":"2024","journal-title":"Int. J. Surg."},{"issue":"8","key":"10.1016\/bs.pbr.2025.08.011_bib45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/156720510793611592","article-title":"Tau in Alzheimer disease and related tauopathies","volume":"7","author":"Iqbal","year":"2010","journal-title":"Curr. Alzheimer Res."},{"issue":"4","key":"10.1016\/bs.pbr.2025.08.011_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA\u2010AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s & Dement"},{"issue":"4","key":"10.1016\/bs.pbr.2025.08.011_bib47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/bs.pbr.2025.08.011_bib48","doi-asserted-by":"crossref","first-page":"1578138","DOI":"10.3389\/fncel.2025.1578138","article-title":"CRISPR\/Cas9-based therapeutics as a promising strategy for management of alzheimer\u2019s disease: progress and prospects","volume":"19","author":"Khan","year":"2025","journal-title":"Front. Cell. Neurosci."},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib49","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2021.17","article-title":"Major cost drivers in assessing the economic burden of alzheimer\u2019s disease: a structured, rapid review","volume":"8","author":"Klie\u00df","year":"2021","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"issue":"12","key":"10.1016\/bs.pbr.2025.08.011_bib50","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/cells14030168","article-title":"Modulating neuroinflammation as a prospective therapeutic target in Alzheimer\u2019s disease","volume":"14","author":"Lee","year":"2025","journal-title":"Cells"},{"key":"10.1016\/bs.pbr.2025.08.011_bib52","doi-asserted-by":"crossref","unstructured":"Lee L.H., Shineman D.W., Fillit H.M. 2010. A diverse portfolio of novel drug discovery efforts for Alzheimer\u2019s disease: Meeting report from the 11th International Conference on Alzheimer\u2019s Drug Discovery, 27\u201328 September 2010, Jersey City, NJ, USA. Springer; 2010.","DOI":"10.1186\/alzrt57"},{"key":"10.1016\/bs.pbr.2025.08.011_bib53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.12703\/r\/12-24","article-title":"Recent advances in understanding Alzheimer\u2019s disease: diagnosis and management strategies","volume":"12","author":"Marin","year":"2023","journal-title":"Fac. Rev."},{"issue":"9","key":"10.1016\/bs.pbr.2025.08.011_bib54","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3390\/ph15091039","article-title":"Leukotrienes vs. Montelukast\u2014activity, metabolism, and toxicity hints for repurposing","volume":"15","author":"Marques","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/bs.pbr.2025.08.011_bib55","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.neurobiolaging.2010.08.017","article-title":"Epigenetic mechanisms in Alzheimer\u2019s disease","volume":"32","author":"Mastroeni","year":"2011","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/bs.pbr.2025.08.011_bib56","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/alz.12190","article-title":"Alzheimer\u2019s & dementia: the journal of the Alzheimer\u2019s association","volume":"17","author":"Mecca","year":"2020","journal-title":"Alzheimer\u2019s & Dementia: J. Alzheimer\u2019s Assoc."},{"key":"10.1016\/bs.pbr.2025.08.011_bib57","series-title":"Datablitz des neurosciences cliniques-ULi\u00e8ge","article-title":"Toward a biological definition of Alzheimer\u2019s disease","year":"2018"},{"issue":"6","key":"10.1016\/bs.pbr.2025.08.011_bib58","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3390\/ph3061812","article-title":"Non-steroidal anti-inflammatory drugs in Alzheimer\u2019s disease and parkinson\u2019s disease: reconsidering the role of neuroinflammation","volume":"3","author":"Moore","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib59","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer\u2019s disease and the amyloid-\u03b2 peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/bs.pbr.2025.08.011_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-323-85538-9.00005-5","article-title":"The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension","volume":"192","author":"Olszewska","year":"2023","journal-title":"Handb. Clin. Neurol."},{"issue":"9","key":"10.1016\/bs.pbr.2025.08.011_bib61","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.3390\/jpm12091485","article-title":"iPSCs in neurodegenerative disorders: a unique platform for clinical research and personalized Medicine","volume":"12","author":"Pandey","year":"2022","journal-title":"J. Personalized Med."},{"key":"10.1016\/bs.pbr.2025.08.011_bib62","doi-asserted-by":"crossref","first-page":"3245935","DOI":"10.1155\/2016\/3245935","article-title":"Tau-Centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease","volume":"2016","author":"Panza","year":"2016","journal-title":"Biomed. Res. Int."},{"issue":"6","key":"10.1016\/bs.pbr.2025.08.011_bib63","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/pharmaceutics14061117","article-title":"Therapeutic approach to Alzheimer\u2019s disease: current treatments and new perspectives","volume":"14","author":"Pardo-Moreno","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib64","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3892\/ijmm.2022.5208","article-title":"Role of non-coding RNAs as biomarkers and the application of omics technologies in Alzheimer\u2019s disease","volume":"51","author":"Pierouli","year":"2022","journal-title":"Int. J. Mol. Med."},{"issue":"7329","key":"10.1016\/bs.pbr.2025.08.011_bib65","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.pbr.2025.08.011_bib66","article-title":"Donanemab: appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib67","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s40001-024-01987-1","article-title":"Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives","volume":"29","author":"Rahimi Darehbagh","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/bs.pbr.2025.08.011_bib68","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-019-09849-y","article-title":"Next generation precision medicine: CRISPR-mediated genome editing for the treatment of neurodegenerative disorders","volume":"14","author":"Raikwar","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/bs.pbr.2025.08.011_bib69","doi-asserted-by":"crossref","unstructured":"Rashad, A., Rasool, A., Shaheryar, M., Sarfraz, A., Sarfraz, Z., Robles-Velasco, K., et al., (Eds.), 2022. Donanemab for Alzheimer\u2019s disease: a systematic review of clinical trials. Healthcare; MDPI.","DOI":"10.3390\/healthcare11010032"},{"issue":"11","key":"10.1016\/bs.pbr.2025.08.011_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079771","article-title":"Consortium AsDG. Alzheimer\u2019s disease: analyzing the missing heritability","volume":"8","author":"Ridge","year":"2013","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/bs.pbr.2025.08.011_bib71","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/pharmaceutics13091397","article-title":"New RNA-based breakthroughs in Alzheimer\u2019s disease diagnosis and therapeutics","volume":"13","author":"Riscado","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00415-025-12975-8","article-title":"Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects","volume":"272","author":"Ruffo","year":"2025","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/bs.pbr.2025.08.011_bib73","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3390\/jpm12050815","article-title":"Deep learning-based diagnosis of Alzheimer\u2019s disease","volume":"12","author":"Saleem","year":"2022","journal-title":"J. Personalized Med."},{"key":"10.1016\/bs.pbr.2025.08.011_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/alz.049653","article-title":"Precision medicine and biomarkers in nutrition science for dementia prevention","volume":"17","author":"Samieri","year":"2021","journal-title":"Alzheimer\u2019s & Dement"},{"issue":"12","key":"10.1016\/bs.pbr.2025.08.011_bib75","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168553","article-title":"Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues","volume":"133","author":"Samudra","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"21","key":"10.1016\/bs.pbr.2025.08.011_bib76","doi-asserted-by":"crossref","first-page":"12924","DOI":"10.3390\/ijms232112924","article-title":"Amyloid beta in aging and Alzheimer\u2019s disease","volume":"23","author":"Sehar","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/bs.pbr.2025.08.011_bib77","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/abhs.abhs_105_24","article-title":"The role of personalized precision medicine in enhancing diagnostic accuracy and clinical outcomes","volume":"4","author":"Sekaran","year":"2025","journal-title":"Adv. Biomed. Health Sci."},{"key":"10.1016\/bs.pbr.2025.08.011_bib78","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","article-title":"Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management","volume":"367","author":"Singh","year":"2024","journal-title":"J. Controlled Rel."},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1535370217733426","article-title":"Biomarkers and their impact on precision medicine","volume":"243","author":"Slikker","year":"2017","journal-title":"Exp. Biol. Med."},{"issue":"4","key":"10.1016\/bs.pbr.2025.08.011_bib80","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3233\/JAD-180638","article-title":"Ethical arguments concerning the use of Alzheimer\u2019s disease biomarkers in individuals with no or mild cognitive impairment: a systematic review and framework for discussion","volume":"66","author":"Smedinga","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/bs.pbr.2025.08.011_bib81","doi-asserted-by":"crossref","first-page":"1511350","DOI":"10.3389\/fnins.2025.1511350","article-title":"Application of artificial intelligence in Alzheimer\u2019s disease: a bibliometric analysis","volume":"19","author":"Song","year":"2025","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib82","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from The National institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer\u2019s & Dement"},{"issue":"4","key":"10.1016\/bs.pbr.2025.08.011_bib83","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cell.2020.01.021","article-title":"A deep learning approach to antibiotic discovery","volume":"180","author":"Stokes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.pbr.2025.08.011_bib84","first-page":"631","article-title":"Personalizing the care and treatment of Alzheimer\u2019s disease: an overview","volume":"14","author":"Svob Strac","year":"2021","journal-title":"Pharmgenomics Pers. Med."},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2025.08.011_bib86","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","article-title":"Alzheimer\u2019s disease: epidemiology and clinical progression","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/bs.pbr.2025.08.011_bib87","doi-asserted-by":"crossref","first-page":"400","DOI":"10.14283\/jpad.2022.49","article-title":"Initiative AsDN. prediction of cognitive decline for enrichment of Alzheimer\u2019s disease clinical trials","volume":"9","author":"Tam","year":"2022","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/bs.pbr.2025.08.011_bib88","first-page":"10","article-title":"Aducanumab: evidence from clinical trial data and controversies","author":"Tampi","year":"2021","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40291-024-00738-6","article-title":"Molecular therapeutics in development to treat Alzheimer\u2019s disease","volume":"29","author":"Tartaglia","year":"2025","journal-title":"Mol. Diagnosis & Ther."},{"issue":"4","key":"10.1016\/bs.pbr.2025.08.011_bib90","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2022.01.016","article-title":"Challenges and hopes for Alzheimer\u2019s disease","volume":"27","author":"Tatulian","year":"2022","journal-title":"Drug. Discov. Today"},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib91","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s10142-023-00979-4","article-title":"Health inequity in genomic personalized medicine in underrepresented populations: a look at the current evidence","volume":"23","author":"Tawfik","year":"2023","journal-title":"Funct. & Integr. Genomics"},{"issue":"9","key":"10.1016\/bs.pbr.2025.08.011_bib92","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jalz.2017.01.020","article-title":"Metabolic network failures in Alzheimer\u2019s disease: a biochemical road map","volume":"13","author":"Toledo","year":"2017","journal-title":"Alzheimer\u2019s & Dement"},{"issue":"7","key":"10.1016\/bs.pbr.2025.08.011_bib93","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/brainsci10070421","article-title":"Science runs and the debate brakes: somatic Gene-Editing as a new tool for Gender-Specific Medicine in alzheimer\u2019s disease","volume":"10","author":"Tozzo","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/bs.pbr.2025.08.011_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101451","article-title":"Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer\u2019s pathology: insights and therapeutic approaches from periphery","volume":"71","author":"Ullah","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/bs.pbr.2025.08.011_bib96","doi-asserted-by":"crossref","first-page":"10298","DOI":"10.1074\/jbc.M112.415141","article-title":"\u03b22 adrenergic receptor, protein kinase a (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in alzheimer disease models","volume":"288","author":"Wang","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.pbr.2025.08.011_bib97","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"issue":"9","key":"10.1016\/bs.pbr.2025.08.011_bib98","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1002\/alz.13104","article-title":"Global rural health disparities in alzheimer\u2019s disease and related dementias: state of the science","volume":"19","author":"Wiese","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/bs.pbr.2025.08.011_bib99","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v12i4.5360","article-title":"Are the newest anti-Alzheimer\u2019s medicines being evaluated under outdated pricing paradigms?","volume":"12","author":"Wilcox","year":"2024","journal-title":"Med. Res. Arch"},{"issue":"9","key":"10.1016\/bs.pbr.2025.08.011_bib100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein e and Alzheimer disease: pathobiology and targeting strategies","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2025.08.011_bib101","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad110","article-title":"Multi-omic integration via similarity network fusion to detect molecular subtypes of ageing","volume":"5","author":"Yang","year":"2023","journal-title":"Brain Commun."},{"key":"10.1016\/bs.pbr.2025.08.011_bib102","unstructured":"Zhang, L.A.W.Q., 2022. The humanistic and economic burden of Alzheimer\u2019s."}],"container-title":["Progress in Brain Research","Precision Medicine in Neurodegenerative Diseases: From Research to Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612325001281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612325001281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:09:15Z","timestamp":1777939755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079612325001281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443430114"],"references-count":102,"URL":"https:\/\/doi.org\/10.1016\/bs.pbr.2025.08.011","relation":{},"ISSN":["0079-6123"],"issn-type":[{"value":"0079-6123","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}